Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following Zevalin consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieved a response to first line therapy over chemotherapy alone. Additionally, Zevalin consolidation did not adversely affect the use of various effective second-line treatments including stem cell transplants in patients who relapsed.

"The FIT study follow-on results are quite impressive when one considers that the median progression free survival for the Zevalin recipients that achieved a complete remission (CR) after induction therapy has not yet been reached with an estimated 67 months compared to 30 months with chemotherapy alone," said James A. Bianco, M.D., CEO of Cell Therapeutics. "A single dose of consolidation that could allow patients with a CR from requiring additional treatment for their NHL for over 3 years represents a significant advancement in the treatment of this disease."

The multinational, randomized phase III FIT study evaluated the benefit and safety of a single infusion of Zevalin in patients with follicular B-cell non-Hodgkin's lymphoma who had achieved a partial remission (PR) or a complete remission / complete remission unconfirmed (CR/CRu) after receiving standard first-line chemotherapy regimens. Patients were randomized to either Zevalin consolidation or no further therapy. The FIT trial results were first presented at the December 2007 ASH annual meeting. The results were subsequently published in Journal of Clinical Oncology 2008 26(32):5156-64. At the 2008 ASH meeting, the investigators prese
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among enterprise ... of localization purchasing in 2015, says Moravia ... a recent study by market research firm Common Sense ... solution for their translation and localization needs. "From a ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Microbiology Testing/Clinical Microbiology Market by Product, ... to 2019" report to their offering. ... of techniques for the detection of infectious diseases. ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Inc. (Nasdaq: VSCP ), a leading provider of quantitative ... (the amount remaining to be recognized from its active and ... clinical research industry), exceeds $35 million which compares to $18 ... than 90% increase. The average duration of the studies included ...
... , FARMINGDALE, N.Y., Sept. 29 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, today announced plans to release fourth quarter ... on Thursday afternoon, October 1, 2009. Michael A. ...
Cached Medicine Technology:VirtualScopics' Project Balance Exceeds a Record $35 Million 2VirtualScopics' Project Balance Exceeds a Record $35 Million 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... 14 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ... March 31, 2009. First Quarter 2009 Results ... a net loss of $3,031,201, or $0.22 per basic and ... $0.13 per basic and diluted share, for the same period ...
... 2013, over 685,000 PCI and 165,000 CABG procedures ... Mass., May 14 According to two new ... and innovations in device technology will shift the ... artery bypass graft (CABG) procedures for unique subgroups ...
... Loss PreventionPISCATAWAY, N.J., May 14 Siemens Hearing Instruments, ... Week, a weeklong observance from May 10 - 16, ... Human Services, Office on Women,s Health ... initiative that encourages women to take steps to live ...
... Inc. (Nasdaq: PMTI ), a leading researcher ... today that Palomar won two patent opposition cases held ... 13, 2009. The opposition hearings concerned European Patents ... which correspond to U.S. Patent Nos. 5,595,568 and 5,735,844. ...
... for Consumers KANSAS CITY, Mo., May 14 ... 8.5 percent,(1) families are living on tighter budgets, and ... Despite these challenges, there are still ways for consumers ... to the National Association of Insurance Commissioners (NAIC). "These ...
... to Provide New Yorkers with Free HIV/AIDS TestingNEW YORK, May ... that The Duane Reade Charitable Foundation has doubled its support ... sponsor of AIDS Walk New York (AWNY). AWNY raises ... AIDS service organizations in the New York tri-state area. ...
Cached Medicine News:Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 5Health News:Clinical Data & Innovation Will Shift PCI and CABG Procedures in Europe 2Health News:Clinical Data & Innovation Will Shift PCI and CABG Procedures in Europe 3Health News:Siemens Hearing Celebrates 10th Annual National Women's Health Week 2Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 2Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 3Health News:Palomar Wins Two European Hair Removal Patent Opposition Hearings 4Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 2Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 3Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 4Health News:Health Insurance: Stay Protected Amid Layoffs, Budget Cuts 5Health News:Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York 2
... Walking Brace is designed to add the ... PneumaticWalker™ (sold separately). When inserted into the ... cuff surrounds the foot and ankle with ... swelling, and pain.,All Cryo/Cuffs can be ordered ...
... reduce swelling and minimize pain while allowing full ... apply - it slips on like a sock, ... It features bilateral spiral stays that move ... stability. This is an excellent support for ...
... with three regulated communicative chambers. It's one ... of low profile pneumatics to dramatically increase ... in other stirrups. The "slow rebound" air ... is enclosed and protected to prevent puncture. ...
... problem enough for your patients. Now you can ... treatment for foot and ankle fractures and soft ... combination of prefabricated brace and open foam liner ... standards of safety. The storm can be used ...
Medicine Products: